Conference Day 2 - November 8, 2017
Day Two
08:50
Chairman's opening remarks
STAKEHOLDER ENGAGEMENT
09:20
Innovation in Drug Discovery and Development: The Role of Genetics
- Why the push towards precision medicine will continue to increase and why policymakers must align their efforts
- Solving the issue of reimbursement for diagnostics
- How definitions of precision value in Europe and the USA have diverged
09:40
PANEL SESSION: Pricing and reimbursement: guaranteeing market access for precision drugs
- Collaborating with payers in order to ensure cost containment in personalized health does not affect expanded patient access
- Optimizing value propositions to allay payer and provider scepticism around the cost-benefit balance of precision medicine
- The role of pharmacy benefit managers and pay-for-play programs in precision medicine pathways
10:20
Supporting immunotherapy development with pre-clinical biomarker research
- How biomarker discovery teams can work with clinical counterparts for a streamlined development strategy
- Modelling biomarker development in the pre-clinical stage of research
10:40 NETWORKING COFFEE BREAK
MANUFACTURING
BIG DATA
Discovery & Development
11:20The next wave of gene editing in a multi-stakeholder environment
- Circumventing ethical concerns around gene editing of early human cells
- Payers: Will insurance companies pay for personalized gene editing, and where funding will come from if not
- Alternate uses for CRISPR: controlling genes rather than editing them
Diagnostics & Data
11:20More than a match for cancer: outcomes and developments of the NCI’s MATCH program
- Hear how the NCI has developed a manageable strategy for patient recruitment in the MATCH program
- An analysis of the quid pro quo needed to build collaboration between the NCI and the pharmaceutical industry
- Why the program aims for a 25% rate of rare cancers in patient recruitment and what results this has yielded
Discovery & Development
11:40Tissue-based cell therapy: a new route for precision med manufacturing
- Delivering functional, architectural tissue to replace or augment organ function
- Permitting delivery of gene therapy / iPSC / CART modified cells to solid organ targets
- Providing a highly reproducible, automated way to enable tissue engraftment and vascularization into target organs
Diagnostics & Data
11:40My Research Legacy – a project at the intersection of big data, genomics and medicine
- Building a platform for millions of patients by curating strategic partnerships in tech
- Driving personalized medicine and patient adherence solutions through the AHA’s big data platform
Discovery & Development
Short-term costs of integrating whole genome sequencing into cardiology and primary care.
- Variant interpretation, confirmation and disclosure add substantially to the cost of sequencing
- The impact of sequencing on downstream health care costs may be minimal
- Larger, long-term studies are needed to understand the full cost and health impact
Kurt Christensen, Instructor in Medicine, Brigham and Women's Hospital
Diagnostics & Data
12:00The Use of Long Read Sequencing to Investigate the HER2 Locus in Breast Cancer
- HER2 is amplified in many breast cancers, but we do not know truly understand the structure of the amplified sequence
- We have used long read Oxford Nanopore Sequencing to Investigate the HER2 Locus
- These long reads have given us an enhanced view of the genetics and can help us better understand ways to treat Breast Cancer
Jeffrey Rosenfeld, Assistant Professor of Pathology and Laboratory Medicine, Rutgers University
12:20
INTERACTIVE ROUNDTABLE DISCUSSIONS
Adaptive trials – where companion diagnostics fit in
Animal models in pre-clinical biomarker exploration
Epigenetics - modifying gene expression and studying the outcomes
Finding funding – lobbying for increased federal support for precision medicine
Genetic data for drug discovery
Human Cell Atlas – discussing the possibilities and pitfalls
International data sharing – the obstacles and the opportunities
Monica Mallampalli, Women's Health & Board of Directors,, SCAD Alliance
Medical devices – the interplay between test developer and drug developer
Mental health – are genomics enough of a variable?
Patient adherence – is it achievable and is it valuable?
Prenatal diagnostics – considerations around counselling and education
Psychological aspects of genomic screening for patients
The Journey to Building a Comprehensive Precision Oncology Program at an Academic Medical Center
13:00
NETWORKING LUNCH
INDUSTRY PHARMACOGENOMICS WORKING GROUP
14:20INDUSTRY PHARMACOGENOMICS WORKING GROUP
INDUSTRY PHARMACOGENOMICS WORKING GROUP (I-PWG)
Introduction to I-PWG and our intent for the workshop
In this introduction, we will describe I-PWG, our composition, mission, and goals. We will describe pharmacogenomics and its importance in drug development, activity within the industry to facilitate the study of pharmacogenomics and the modalities that we leverage to contribute to the development of precision medicines.
Moderator: Michelle Penny, Senior Director, Head of Computational Biology and Genomics
Biogen
Talk 1: NGS and its evolving application in pharmacogenomics
Learn how companies are utilizing NGS to inform the discovery and development of safe and effective medicine. Data from an I-PWG survey on NGS practices will be shared.
Presenter: Charles Paulding, Director Pharmacogenomics, Regeneron Pharmaceuticals, Inc.
Talk 2: Optimizing Pharmacogenomics Sampling in Clinical Trials: Current Practices for collecting DNA
Hear about current solutions within industry, best practices, and challenges, including country specific examples, to obtaining PGx populations that are representative of the global clinical trial population.
Presenter: Anita Nelsen, Head of Genomic Medicine, PAREXEL International
Talk 3: Closing the knowledge gap:
Pharmacogenomics education and resources for the patient, site staff and ethics committees
This presentation will highlight the need for pharmacogenomics education and describe some of the resources available through I-PWG.
Presenter: Sandra Prucka, Director of Genetic Counseling for Clinical Services, Department of Medical & Molecular Genetics, Indiana University, School of Medicine
Panel Discussion- Hot topics
Moderator:
Michelle Penny, Senior Director, Head of Computational Biology and Genomics, Biogen Idec
Panelists:
Charles Paulding, Director Predictive Medicine, Genetics, Regeneron Pharmaceuticals
Anita Head, Head of Genomic Medicine, PAREXEL International
Sandra Prucka, Director of Genetic Counseling for Clinical Services, Department of Medical & Molecular Genetics, Indiana University, School of Medicine
Rebecca Blanchard, Head of Clinical Pharmacogenomics, Executive Director, MSD
Kechi Anyadike, Senior Manager, Precision Medicine, Regeneron Pharmaceuticals
Jean-Claude Marshall, Head of Clinical Genetics and Biospecimens, Pfizer
Kechi Anyadike, Senior Manager of Precision Medicine, Regeneron
Introduction to I-PWG and our intent for the workshop
In this introduction, we will describe I-PWG, our composition, mission, and goals. We will describe pharmacogenomics and its importance in drug development, activity within the industry to facilitate the study of pharmacogenomics and the modalities that we leverage to contribute to the development of precision medicines.
Moderator: Michelle Penny, Senior Director, Head of Computational Biology and Genomics
Biogen
Talk 1: NGS and its evolving application in pharmacogenomics
Learn how companies are utilizing NGS to inform the discovery and development of safe and effective medicine. Data from an I-PWG survey on NGS practices will be shared.
Presenter: Charles Paulding, Director Pharmacogenomics, Regeneron Pharmaceuticals, Inc.
Talk 2: Optimizing Pharmacogenomics Sampling in Clinical Trials: Current Practices for collecting DNA
Hear about current solutions within industry, best practices, and challenges, including country specific examples, to obtaining PGx populations that are representative of the global clinical trial population.
Presenter: Anita Nelsen, Head of Genomic Medicine, PAREXEL International
Talk 3: Closing the knowledge gap:
Pharmacogenomics education and resources for the patient, site staff and ethics committees
This presentation will highlight the need for pharmacogenomics education and describe some of the resources available through I-PWG.
Presenter: Sandra Prucka, Director of Genetic Counseling for Clinical Services, Department of Medical & Molecular Genetics, Indiana University, School of Medicine
Panel Discussion- Hot topics
Moderator:
Michelle Penny, Senior Director, Head of Computational Biology and Genomics, Biogen Idec
Panelists:
Charles Paulding, Director Predictive Medicine, Genetics, Regeneron Pharmaceuticals
Anita Head, Head of Genomic Medicine, PAREXEL International
Sandra Prucka, Director of Genetic Counseling for Clinical Services, Department of Medical & Molecular Genetics, Indiana University, School of Medicine
Rebecca Blanchard, Head of Clinical Pharmacogenomics, Executive Director, MSD
Kechi Anyadike, Senior Manager, Precision Medicine, Regeneron Pharmaceuticals
Jean-Claude Marshall, Head of Clinical Genetics and Biospecimens, Pfizer
Kechi Anyadike, Senior Manager of Precision Medicine, Regeneron
MULTIOMIC DATA
14:20Harnessing patient advocacy in the effort to accelerate precision medicine discovery and development
- Rare disease: how the burden is an obstacle to patient engagement and how patient advocacy can overcome it
- Patient privacy and how to empower patient advocates and caregivers to champion genomic research
- How pharma can build stronger relationships with rare disease and precision medicine foundations
MULTIOMIC DATA
14:40Enabling patients to engage with their data
- Why offering patient choice leads to increased engagement and adherence with an economic benefit for pharma and physicians
- How unprecedented privacy controls in the Reg4All registry allay patient concerns and enable future research
MULTIOMIC DATA
15:00Multi-omics: integrating multiple data sources into one precision medicine proposal
- Combining multiple ‘omics’ into a clear value proposition for patient personalization
- Understanding the value of advanced analytical technology in order to integrate data for decision-making processes
- Leveraging patient-centered data in a meaningful way by understanding physician needs
MULTIOMIC DATA
15:20Wearables for precision medicine
- Promoting the use of wearables for acute and chronic illness detection
- Collaborating with tech and academia to enable investment from pharma
- Reimbursement: plotting value propositions for companion wearables to fund future advances
15:50
CLOSING REMARKS
CONFERENCE ENDS
last published: 31/Oct/17 23:05 GMT
Organiser
